Description
The 3D12 monoclonal antibody specifically recognizes Human Leukocyte Antigen E (HLA-E) that is widely expressed on leucocytes and some other cell types. Cell surface HLA-E is normally expressed as a noncovalent complex comprised of the ~45 kDa type I transmembrane, HLA-E heavy-chain glycoprotein, the ~12 kDa invariant β2-microglobulin (β2m) light chain, and a short bound peptide. Human HLA-E represents a nonclassical Major Histocompatibility Complex class I (MHC class Ib) molecule that is homologous to mouse H-2 Qa-1. Although structurally related to the classical, highly polymorphic MHC class Ia antigens (HLA-A, -B, -C), HLA-E shows limited polymorphism. HLA-E functions in the regulation or self-nonself discrimination of innate and adaptive immune responses. In addition to binding self peptides, the HLA-E complex can selectively bind and present peptides derived from bacterial or viral pathogen-infected cells, stressed cells, or tumor cells to elicit antigen-specific, HLA-E-restricted CD8+ T cell responses. The cell surface HLA-E complex likewise serves as a ligand for heterodimeric CD94:NKG2A inhibitory and CD94:NKG2C activating receptors that are differentially expressed on NK cells and some T cells. These ligand:receptor interactions can either suppress or promote NK or T cell-mediated responses. The 3D12 antibody reportedly binds to both free or complexed HLA-E heavy chain and can block HLA-E-dependent function.
BD™ CompBeads can be used as surrogates to assess fluorescence spillover (Compensation). When fluorochrome conjugated antibodies are bound to CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and CompBead to ensure that BD Comp beads are appropriate for your specific cellular application. For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
2. Researchers should determine the optimal concentration of this reagent for their individual applications.
3. An isotype control should be used at the same concentration as the antibody of interest.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
6. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
7. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
8. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
9. Pacific Blue™ is a trademark of Molecular Probes, Inc., Eugene, OR.
10. BD Horizon Brilliant Violet 421 is covered by one or more of the following US patents: 8,158,444; 8,362,193; 8,575,303; 8,354,239.
